Endovascular options in the treatment of delayed ischemic neurological deficits due to cerebral vasospasm.

Christopher S. Eddleman, Michael C. Hurley, Andrew M. Naidech, H. Hunt Batjer, Bernard R. Bendok

Research output: Contribution to journalArticle

Abstract

The second leading cause of death and disability in patients with aneurysmal subarachnoid hemorrhage (SAH) is delayed cerebral ischemia due to vasospasm. Although up to 70% of patients have been shown to have angiographic evidence of vasospasm, only 20-30% will present with clinical changes, including mental status changes and neurological deficits that necessitate acute management. Endovascular capabilities have progressed to become viable options in the treatment of cerebral vasospasm. The rationale for intraarterial therapy includes the fact that morbidity and mortality rates have not changed in recent years despite optimized noninvasive medical care. In this report, the authors discuss the most common endovascular options-namely intraarterial vasodilators and transluminal balloon angioplasty-from the standpoint of mechanism, efficacy, limitations, and complications as well as the treatment algorithms for cerebral vasospasm used at our institution.

Original languageEnglish (US)
JournalNeurosurgical Focus
Volume26
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Intracranial Vasospasm
Balloon Angioplasty
Subarachnoid Hemorrhage
Brain Ischemia
Vasodilator Agents
Angioplasty
Cause of Death
Therapeutics
Morbidity
Mortality

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Endovascular options in the treatment of delayed ischemic neurological deficits due to cerebral vasospasm. / Eddleman, Christopher S.; Hurley, Michael C.; Naidech, Andrew M.; Batjer, H. Hunt; Bendok, Bernard R.

In: Neurosurgical Focus, Vol. 26, No. 3, 2009.

Research output: Contribution to journalArticle

Eddleman, Christopher S. ; Hurley, Michael C. ; Naidech, Andrew M. ; Batjer, H. Hunt ; Bendok, Bernard R. / Endovascular options in the treatment of delayed ischemic neurological deficits due to cerebral vasospasm. In: Neurosurgical Focus. 2009 ; Vol. 26, No. 3.
@article{19e5b5ba117f4628a6d98da49b920533,
title = "Endovascular options in the treatment of delayed ischemic neurological deficits due to cerebral vasospasm.",
abstract = "The second leading cause of death and disability in patients with aneurysmal subarachnoid hemorrhage (SAH) is delayed cerebral ischemia due to vasospasm. Although up to 70{\%} of patients have been shown to have angiographic evidence of vasospasm, only 20-30{\%} will present with clinical changes, including mental status changes and neurological deficits that necessitate acute management. Endovascular capabilities have progressed to become viable options in the treatment of cerebral vasospasm. The rationale for intraarterial therapy includes the fact that morbidity and mortality rates have not changed in recent years despite optimized noninvasive medical care. In this report, the authors discuss the most common endovascular options-namely intraarterial vasodilators and transluminal balloon angioplasty-from the standpoint of mechanism, efficacy, limitations, and complications as well as the treatment algorithms for cerebral vasospasm used at our institution.",
author = "Eddleman, {Christopher S.} and Hurley, {Michael C.} and Naidech, {Andrew M.} and Batjer, {H. Hunt} and Bendok, {Bernard R.}",
year = "2009",
doi = "10.3171/2008.11.FOCUS08278",
language = "English (US)",
volume = "26",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - Endovascular options in the treatment of delayed ischemic neurological deficits due to cerebral vasospasm.

AU - Eddleman, Christopher S.

AU - Hurley, Michael C.

AU - Naidech, Andrew M.

AU - Batjer, H. Hunt

AU - Bendok, Bernard R.

PY - 2009

Y1 - 2009

N2 - The second leading cause of death and disability in patients with aneurysmal subarachnoid hemorrhage (SAH) is delayed cerebral ischemia due to vasospasm. Although up to 70% of patients have been shown to have angiographic evidence of vasospasm, only 20-30% will present with clinical changes, including mental status changes and neurological deficits that necessitate acute management. Endovascular capabilities have progressed to become viable options in the treatment of cerebral vasospasm. The rationale for intraarterial therapy includes the fact that morbidity and mortality rates have not changed in recent years despite optimized noninvasive medical care. In this report, the authors discuss the most common endovascular options-namely intraarterial vasodilators and transluminal balloon angioplasty-from the standpoint of mechanism, efficacy, limitations, and complications as well as the treatment algorithms for cerebral vasospasm used at our institution.

AB - The second leading cause of death and disability in patients with aneurysmal subarachnoid hemorrhage (SAH) is delayed cerebral ischemia due to vasospasm. Although up to 70% of patients have been shown to have angiographic evidence of vasospasm, only 20-30% will present with clinical changes, including mental status changes and neurological deficits that necessitate acute management. Endovascular capabilities have progressed to become viable options in the treatment of cerebral vasospasm. The rationale for intraarterial therapy includes the fact that morbidity and mortality rates have not changed in recent years despite optimized noninvasive medical care. In this report, the authors discuss the most common endovascular options-namely intraarterial vasodilators and transluminal balloon angioplasty-from the standpoint of mechanism, efficacy, limitations, and complications as well as the treatment algorithms for cerebral vasospasm used at our institution.

UR - http://www.scopus.com/inward/record.url?scp=65249163366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249163366&partnerID=8YFLogxK

U2 - 10.3171/2008.11.FOCUS08278

DO - 10.3171/2008.11.FOCUS08278

M3 - Article

C2 - 19249962

VL - 26

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 3

ER -